准终端通路减少了大脑补充激活,粉样蛋白负载和突触损失,并改善了痴呆症小鼠模型中的认知
Wioleta M Zelek1, Ryan J Bevan1, Bryan Paul Morgan1
1UK Dementia Research Institute Cardiff and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales CF14 4XN, United Kingdom.
Brain, behavior, and immunity
|March 14, 2024
概括
该研究发现,抑制膜攻击复合体 (MAC),补充系统的组成部分,减少了阿尔茨海默氏症.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 在阿尔茨海默病 (AD) 和其小鼠模型中观察到补充系统调节失调.
- 虽然像MAC这样的补充效应因子与AD病变发生有关,但它们的具体作用尚不清楚.
- 膜攻击复合体 (MAC) 是补体级联的催化和促炎效应体.
研究的目的:
- 用AppNL-G-F小鼠模型研究膜攻击复合体 (MAC) 在阿尔茨海默病病理学中的作用.
- 评估针对MAC,特别是C7,用于阿尔茨海默病治疗的治疗潜力.
主要方法:
- 生成AppNL-G-F小鼠缺乏C7,一个重要的MAC组件,以消除MAC形成.
- 向NL-G-F小鼠注射C7阻断单克隆抗体,以评估治疗疗效.
- 在接受治疗和对照组中评估了突触损失,粉样蛋白负载和认知表现.
主要成果:
- 在AppNL-G-F小鼠中的C7缺乏减少了MAC形成,突触损失,粉样蛋白沉积,并改善了认知.
- 在缺乏C7的小鼠中恢复C7导致MAC形成增加和急性突触损失.
- 用C7阻断抗体治疗降低了大脑MAC和粉样蛋白,增加了突触密度,并改善了认知功能.
结论:
- 膜攻击复合体 (MAC) 作为阿尔茨海默病病理学的重要驱动因素.
- 通过抑制C7来向MAC,为阿尔茨海默病提供了一个有前途的治疗策略.
- 专注于MAC组件的补充抑制为AD治疗提供了潜在的途径.
相关概念视频
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113


